MAP2K7 and metastatic melanoma: Recommended therapy for patients with metastatic melanoma with a BRAF V600-mutation includes combination regimens targeting BRAF and MEK (eg, dabrafenib plus trametinib, vemurafenib plus cobimetinib, or encorafenib plus binimetinib).